tiprankstipranks
Relay Therapeutics (RLAY)
NASDAQ:RLAY
US Market
RLAY
Relay Therapeutics
RESEARCH TOOLSreports
Want to see RLAY full AI Analyst Report?

Relay Therapeutics (RLAY) Stock Forecast & Price Target

628 Followers
See the Price Targets and Ratings of:

RLAY Analyst Ratings

Strong Buy
9Ratings
Strong Buy
9 Buy
0 Hold
0 Sell
Based on 9 analysts giving stock ratings to
Relay
Therapeutics
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

RLAY Stock 12 Month Forecast

Average Price Target

$27.63
▲(34.30% Upside)
Based on 9 Wall Street analysts offering 12 month price targets for Relay Therapeutics in the last 3 months. The average price target is $27.63 with a high forecast of $31.00 and a low forecast of $20.00. The average price target represents a 34.30% change from the last price of $20.57.
{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"2":"$2","17":"$17","32":"$32","9.5":"$9.5","24.5":"$24.5"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$31.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":27.625,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$27.63</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[2,9.5,17,24.5,32],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2025","6":"Feb<br/>2026","9":"May<br/>2026","12":"Aug<br/>2026","25":"Aug<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.83,19.766153846153845,20.70230769230769,21.638461538461538,22.574615384615385,23.51076923076923,24.446923076923078,25.38307692307692,26.31923076923077,27.255384615384614,28.191538461538464,29.127692307692307,30.063846153846153,{"y":31,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.83,19.50653846153846,20.18307692307692,20.859615384615385,21.536153846153844,22.212692307692308,22.889230769230767,23.56576923076923,24.24230769230769,24.918846153846154,25.595384615384614,26.271923076923077,26.948461538461537,{"y":27.625,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,18.83,18.919999999999998,19.009999999999998,19.099999999999998,19.189999999999998,19.279999999999998,19.369999999999997,19.46,19.55,19.64,19.73,19.82,19.91,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":3.36,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.66,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.32,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.14,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":7.4,"date":1764547200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.46,"date":1767225600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":8.15,"date":1769904000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.79,"date":1772323200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.77,"date":1775001600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1777593600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 29,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":14.26,"date":1780272000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 28,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":17.76,"date":1782864000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.83,"date":1785542400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}
Highest Price Target$31.00Average Price Target$27.63Lowest Price Target$20.00
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on RLAY
Robert Burns
H.C. Wainwright
H.C. Wainwright
$28→$29
Buy
40.98%
Upside
Reiterated
08/21/26
Relay Therapeutics price target raised to $29 from $28 at H.C. WainwrightRelay Therapeutics price target raised to $29 from $28 at H.C. Wainwright
J.P. Morgan Analyst forecast on RLAY
Priyanka Grover
J.P. Morgan
J.P. Morgan
$28→$31
Buy
50.70%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Mediwound (NASDAQ: MDWD) and Relay Therapeutics (NASDAQ: RLAY)
Citizens JMP Analyst forecast on RLAY
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$21→$26
Buy
26.40%
Upside
Reiterated
08/10/26
Relay Therapeutics price target raised to $26 from $21 at CitizensRelay Therapeutics price target raised to $26 from $21 at Citizens
Barclays Analyst forecast on RLAY
Etzer Darout
Barclays
Barclays
$27→$30
Buy
45.84%
Upside
Reiterated
08/07/26
Relay Therapeutics (RLAY) Receives a Buy from Barclays
JonesTrading Analyst forecast on RLAY
Boris Peaker
JonesTrading
JonesTrading
$20
Buy
-2.77%
Downside
Reiterated
08/07/26
Boris Peaker Reiterates Buy on Relay Therapeutics, Citing Advancing Zovegalisib Phase III Program, Rich 2026–2027 Catalyst Calendar, and Solid Cash Position Supporting Favorable Risk‑Reward
Bank of America Securities Analyst forecast on RLAY
Chi Meng Fong
Bank of America Securities
Bank of America Securities
$21→$25
Buy
21.54%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Relay Therapeutics (NASDAQ: RLAY) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)
TD Cowen Analyst forecast on RLAY
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/06/26
Analyst Reiterates Buy on Relay Therapeutics, Citing Lead Asset Zovegalisib’s Phase 3 Upside and Strong Cash Runway into 2029
Canaccord Genuity Analyst forecast on RLAY
John Newman
Canaccord Genuity
Canaccord Genuity
$29
Buy
40.98%
Upside
Reiterated
08/06/26
Relay Therapeutics: Buy Rating Reaffirmed with Unchanged $29 Price Target on Multiple Upcoming Clinical and Regulatory Catalysts
Goldman Sachs Analyst forecast on RLAY
Salveen Richter
Goldman Sachs
Goldman Sachs
$22→$31
Buy
50.70%
Upside
Reiterated
07/20/26
Relay Therapeutics price target raised to $31 from $22 at Goldman SachsRelay Therapeutics price target raised to $31 from $22 at Goldman Sachs
Guggenheim Analyst forecast on RLAY
Bradley Canino
Guggenheim
Guggenheim
$22→$26
Buy
26.40%
Upside
Reiterated
05/25/26
Guggenheim Keeps Their Buy Rating on Relay Therapeutics (RLAY)
Wells Fargo Analyst forecast on RLAY
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$21
Buy
2.09%
Upside
Reiterated
05/19/26
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (NASDAQ: RLAY) and Wave Life Sciences (NASDAQ: WVE)
Raymond James Analyst forecast on RLAY
Sean McCutcheon
Raymond James
Raymond James
$23→$26
Buy
26.40%
Upside
Reiterated
05/19/26
Relay Therapeutics price target raised to $26 from $23 at Raymond JamesRelay Therapeutics price target raised to $26 from $23 at Raymond James
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
H.C. Wainwright Analyst forecast on RLAY
Robert Burns
H.C. Wainwright
H.C. Wainwright
$28→$29
Buy
40.98%
Upside
Reiterated
08/21/26
Relay Therapeutics price target raised to $29 from $28 at H.C. WainwrightRelay Therapeutics price target raised to $29 from $28 at H.C. Wainwright
J.P. Morgan Analyst forecast on RLAY
Priyanka Grover
J.P. Morgan
J.P. Morgan
$28→$31
Buy
50.70%
Upside
Reiterated
08/14/26
Analysts Offer Insights on Healthcare Companies: Mediwound (NASDAQ: MDWD) and Relay Therapeutics (NASDAQ: RLAY)
Citizens JMP Analyst forecast on RLAY
Silvan Tuerkcan
Citizens JMP
Citizens JMP
$21→$26
Buy
26.40%
Upside
Reiterated
08/10/26
Relay Therapeutics price target raised to $26 from $21 at CitizensRelay Therapeutics price target raised to $26 from $21 at Citizens
Barclays Analyst forecast on RLAY
Etzer Darout
Barclays
Barclays
$27→$30
Buy
45.84%
Upside
Reiterated
08/07/26
Relay Therapeutics (RLAY) Receives a Buy from Barclays
JonesTrading Analyst forecast on RLAY
Boris Peaker
JonesTrading
JonesTrading
$20
Buy
-2.77%
Downside
Reiterated
08/07/26
Boris Peaker Reiterates Buy on Relay Therapeutics, Citing Advancing Zovegalisib Phase III Program, Rich 2026–2027 Catalyst Calendar, and Solid Cash Position Supporting Favorable Risk‑Reward
Bank of America Securities Analyst forecast on RLAY
Chi Meng Fong
Bank of America Securities
Bank of America Securities
$21→$25
Buy
21.54%
Upside
Reiterated
08/07/26
Analysts Offer Insights on Healthcare Companies: Xenon (NASDAQ: XENE), Relay Therapeutics (NASDAQ: RLAY) and Amylyx Pharmaceuticals Inc (NASDAQ: AMLX)
TD Cowen Analyst forecast on RLAY
Yaron Werber
TD Cowen
TD Cowen
―
Buy
―
Reiterated
08/06/26
Analyst Reiterates Buy on Relay Therapeutics, Citing Lead Asset Zovegalisib’s Phase 3 Upside and Strong Cash Runway into 2029
Canaccord Genuity Analyst forecast on RLAY
John Newman
Canaccord Genuity
Canaccord Genuity
$29
Buy
40.98%
Upside
Reiterated
08/06/26
Relay Therapeutics: Buy Rating Reaffirmed with Unchanged $29 Price Target on Multiple Upcoming Clinical and Regulatory Catalysts
Goldman Sachs Analyst forecast on RLAY
Salveen Richter
Goldman Sachs
Goldman Sachs
$22→$31
Buy
50.70%
Upside
Reiterated
07/20/26
Relay Therapeutics price target raised to $31 from $22 at Goldman SachsRelay Therapeutics price target raised to $31 from $22 at Goldman Sachs
Guggenheim Analyst forecast on RLAY
Bradley Canino
Guggenheim
Guggenheim
$22→$26
Buy
26.40%
Upside
Reiterated
05/25/26
Guggenheim Keeps Their Buy Rating on Relay Therapeutics (RLAY)
Wells Fargo Analyst forecast on RLAY
Eva Fortea Verdejo
Wells Fargo
Wells Fargo
$21
Buy
2.09%
Upside
Reiterated
05/19/26
Analysts Offer Insights on Healthcare Companies: Relay Therapeutics (NASDAQ: RLAY) and Wave Life Sciences (NASDAQ: WVE)
Raymond James Analyst forecast on RLAY
Sean McCutcheon
Raymond James
Raymond James
$23→$26
Buy
26.40%
Upside
Reiterated
05/19/26
Relay Therapeutics price target raised to $26 from $23 at Raymond JamesRelay Therapeutics price target raised to $26 from $23 at Raymond James
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
PTGXProtagonist Therapeutics
AXGNAxoGen
ATECAlphatec Holdings
CABACabaletta Bio
ONCBeOne Medicines
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Relay Therapeutics

3 Months
Salveen RichterGoldman Sachs
Success Rate
6/10 ratings generated profit
60%
Average Return
+9.34%
Copying Salveen Richter's trades and holding each position for 3 Months would result in 60.00% of your transactions generating a profit, with an average return of +9.34% per trade.
1 Year
Salveen RichterGoldman Sachs
Success Rate
5/10 ratings generated profit
50%
Average Return
+20.83%
Copying Salveen Richter's trades and holding each position for 1 Year would result in 50.00% of your transactions generating a profit, with an average return of +20.83% per trade.
2 Years
Robert BurnsH.C. Wainwright
Success Rate
14/19 ratings generated profit
74%
Average Return
+162.21%
Copying Robert Burns's trades and holding each position for 2 Years would result in 73.68% of your transactions generating a profit, with an average return of +162.21% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

RLAY Analyst Recommendation Trends

Rating
Apr 26
May 26
Jun 26
Jul 26
Aug 26
Strong Buy
9
20
16
13
3
Buy
8
9
12
10
14
Hold
2
3
4
2
1
Sell
0
0
0
0
0
Strong Sell
0
0
0
0
0
total
19
32
32
25
18
In the current month, RLAY has received 17 Buy Ratings, 1 Hold Ratings, and 0 Sell Ratings. RLAY average Analyst price target in the past 3 months is 27.63.
Each month's total comprises the sum of three months' worth of ratings.

RLAY Financial Forecast

RLAY Earnings Forecast

Next quarter’s earnings estimate for RLAY is -$0.40 with a range of -$0.43 to -$0.34. The previous quarter’s EPS was -$0.41. RLAY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RLAY has Performed in-line its overall industry.
Next quarter’s earnings estimate for RLAY is -$0.40 with a range of -$0.43 to -$0.34. The previous quarter’s EPS was -$0.41. RLAY beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.80% of the time in the same period. In the last calendar year RLAY has Performed in-line its overall industry.

RLAY Sales Forecast

Next quarter’s sales forecast for RLAY is $1.62M with a range of $0.00 to $13.50M. The previous quarter’s sales results were $350.00K. RLAY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RLAY has Performed in-line its overall industry.
Next quarter’s sales forecast for RLAY is $1.62M with a range of $0.00 to $13.50M. The previous quarter’s sales results were $350.00K. RLAY beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.04% of the time in the same period. In the last calendar year RLAY has Performed in-line its overall industry.

RLAY Stock Forecast FAQ

What is RLAY’s average 12-month price target, according to analysts?
Based on analyst ratings, Relay Therapeutics’s 12-month average price target is 27.63.
    What is RLAY’s upside potential, based on the analysts’ average price target?
    Relay Therapeutics has 34.30% upside potential, based on the analysts’ average price target.
      Can I see which stocks the top-ranking analysts are rating?
      Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
        How can I follow the stock ratings of top Wall Street analysts?
        Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
          Is RLAY a Buy, Sell or Hold?
          Relay Therapeutics has a consensus rating of Strong Buy which is based on 9 buy ratings, 0 hold ratings and 0 sell ratings.
            What is Relay Therapeutics’s price target?
            The average price target for Relay Therapeutics is 27.63. This is based on 9 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
            The highest analyst price target is $31.00 ,the lowest forecast is $20.00. The average price target represents 34.30% Increase from the current price of $20.57.
              What do analysts say about Relay Therapeutics?
              Relay Therapeutics’s analyst rating consensus is a Strong Buy. This is based on the ratings of 9 Wall Streets Analysts.
                How can I buy shares of RLAY?
                Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.